Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
The Duchess of Cambridge today made her last public appearance before the birth of her second child, with the Duke saying "any day now".
The tomb that houses Richard III's coffin has been revealed in Leicester Cathedral.
Launching Plaid Cymru's campaign, leader Leanne Wood, says the general election offers Wales an "unprecedented opportunity" for change.